Arbutus Biopharma Corporation
ABUS
$4.58
$0.173.86%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 160.72M | -33.50M | -42.28M | -54.25M | -76.57M |
| Total Depreciation and Amortization | 44.00K | 363.00K | 685.00K | 1.01M | 1.36M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -962.00K | 3.52M | 8.37M | 8.75M | 10.97M |
| Change in Net Operating Assets | -194.16M | -10.02M | -12.05M | -15.70M | 5.30M |
| Cash from Operations | -34.36M | -39.64M | -45.27M | -60.19M | -58.95M |
| Capital Expenditure | -- | -- | -86.00K | -86.00K | -87.00K |
| Sale of Property, Plant, and Equipment | 364.00K | 364.00K | 9.00K | 9.00K | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 6.07M | 15.22M | 30.43M | 28.46M | 22.69M |
| Cash from Investing | 6.43M | 15.58M | 30.35M | 28.39M | 22.60M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 14.56M | 5.72M | 5.50M | 6.43M | 30.35M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 14.56M | 5.72M | 5.50M | 6.43M | 30.35M |
| Foreign Exchange rate Adjustments | 0.00 | 14.00K | -20.00K | -3.00K | -32.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -13.37M | -18.32M | -9.44M | -25.38M | -6.03M |